Plexxikon clinical trials

Acquired by Daiichi Sankyo

The registry lists 7 studies whose lead sponsor is Plexxikon. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 24, 2018.

Studies

Recruiting first, then most recently updated. Showing 7 of 7. All Daiichi Sankyo studies →

• A Study of PLX51107 in Advanced MalignanciesTerminatedNCT02683395Phase 1

  Sponsor listed in the registry: Plexxikon · Plexxikon — acquired company within the Daiichi Sankyo group

• Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid TumorsTerminatedNCT01804530Phase 1

  Sponsor listed in the registry: Plexxikon · Plexxikon — acquired company within the Daiichi Sankyo group

• A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell TumorTerminatedNCT02673736Phase 1

  Sponsor listed in the registry: Plexxikon · Plexxikon — acquired company within the Daiichi Sankyo group

• Safety Study of PLX4032 in Patients With Solid TumorsCompletedNCT00405587Phase 1

  Sponsor listed in the registry: Plexxikon · Plexxikon — acquired company within the Daiichi Sankyo group

• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult VolunteersCompletedNCT01282684Phase 1

  Sponsor listed in the registry: Plexxikon · Plexxikon — acquired company within the Daiichi Sankyo group

• Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving MethotrexateWithdrawnNCT01090570Phase 1

  Sponsor listed in the registry: Plexxikon · Plexxikon — acquired company within the Daiichi Sankyo group

• Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving MethotrexateCompletedNCT01329991Phase 1

  Sponsor listed in the registry: Plexxikon · Plexxikon — acquired company within the Daiichi Sankyo group